Trials
Sites
Patients Enrolled
Countries
What we do
ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.
ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the leading clinicians and researchers in below the belt cancers, and communicate frequently and effectively with the broader community along the way.
What we do
ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.
ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the leading clinicians and researchers in below the belt cancers, and communicate frequently and effectively with the broader community along the way.
Telehealth and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Teleheath and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Latest News
The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer
To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.
TheraP (ANZUP 1603) Clinical Trial Results in Lancet Oncology: Lutetium PSMA-617 is an alternative to Cabazitaxel Chemotherapy in Extended Follow-Up Study
This week the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) TheraP trial (ANZUP 1603) featured in The Lancet Oncology reported overall
ANZUP’s Phase 2 ENZA-p study (ANZUP 1901) interim results show a 58% reduction in the rate of PSA progression
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) today announced interim results of their Phase 2 ENZA-p (ANZUP 1901) study, which
The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer
To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.
TheraP (ANZUP 1603) Clinical Trial Results in Lancet Oncology: Lutetium PSMA-617 is an alternative to Cabazitaxel Chemotherapy in Extended Follow-Up Study
This week the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) TheraP trial (ANZUP 1603) featured in The Lancet Oncology reported overall
ANZUP’s Phase 2 ENZA-p study (ANZUP 1901) interim results show a 58% reduction in the rate of PSA progression
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) today announced interim results of their Phase 2 ENZA-p (ANZUP 1901) study, which